AngioDynamics Total Liab from 2010 to 2025

ANGO Stock  USD 10.34  0.19  1.80%   
AngioDynamics Total Liabilities yearly trend continues to be very stable with very little volatility. Total Liabilities is likely to drop to about 128.9 M. Total Liabilities is the total amount of all liabilities that AngioDynamics has, including both short-term and long-term liabilities. View All Fundamentals
 
Total Liabilities  
First Reported
2002-05-31
Previous Quarter
97 M
Current Value
104.8 M
Quarterly Volatility
86.8 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check AngioDynamics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AngioDynamics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 18.5 M, Interest Expense of 1.7 M or Total Revenue of 246.7 M, as well as many indicators such as Price To Sales Ratio of 0.91, Dividend Yield of 0.0 or PTB Ratio of 1.17. AngioDynamics financial statements analysis is a perfect complement when working with AngioDynamics Valuation or Volatility modules.
  
Check out the analysis of AngioDynamics Correlation against competitors.
To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.

Latest AngioDynamics' Total Liab Growth Pattern

Below is the plot of the Total Liab of AngioDynamics over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. AngioDynamics' Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AngioDynamics' overall financial position and show how it may be relating to other accounts over time.
Total Liab10 Years Trend
Slightly volatile
   Total Liab   
       Timeline  

AngioDynamics Total Liab Regression Statistics

Arithmetic Mean168,068,753
Geometric Mean149,785,532
Coefficient Of Variation38.21
Mean Deviation51,839,216
Median162,877,000
Standard Deviation64,214,228
Sample Variance4123.5T
Range244.1M
R-Value(0.36)
Mean Square Error3855.1T
R-Squared0.13
Significance0.17
Slope(4,814,563)
Total Sum of Squares61852T

AngioDynamics Total Liab History

2025128.9 M
2024128.9 M
2023112.1 M
2022154.3 M
2021128.3 M
2020122 M
2019139.6 M

About AngioDynamics Financial Statements

AngioDynamics investors utilize fundamental indicators, such as Total Liab, to predict how AngioDynamics Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Total Liabilities128.9 M128.9 M
When determining whether AngioDynamics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AngioDynamics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Angiodynamics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Angiodynamics Stock:
Check out the analysis of AngioDynamics Correlation against competitors.
To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AngioDynamics. If investors know AngioDynamics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AngioDynamics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.59)
Revenue Per Share
7.064
Quarterly Revenue Growth
(0.08)
Return On Assets
(0.06)
Return On Equity
(0.76)
The market value of AngioDynamics is measured differently than its book value, which is the value of AngioDynamics that is recorded on the company's balance sheet. Investors also form their own opinion of AngioDynamics' value that differs from its market value or its book value, called intrinsic value, which is AngioDynamics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AngioDynamics' market value can be influenced by many factors that don't directly affect AngioDynamics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AngioDynamics' value and its price as these two are different measures arrived at by different means. Investors typically determine if AngioDynamics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AngioDynamics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.